| Online-Ressource |
Verfasst von: | Bauer, Lukas [VerfasserIn]  |
| Blank, Susanne [VerfasserIn]  |
| Schmidt, Thomas [VerfasserIn]  |
Titel: | A novel pretherapeutic gene expression-based risk score for treatment guidance in gastric cancer |
Verf.angabe: | L. Bauer, A. Hapfelmeier, S. Blank, M. Reiche, J. Slotta-Huspenina, M. Jesinghaus, A. Novotny, T. Schmidt, B. Grosser, M. Kohlruss, W. Weichert, K. Ott & G. Keller |
Jahr: | 2018 |
Umfang: | 6 S. |
Teil: | volume:29 |
| year:2018 |
| number:1 |
| pages:127-132 |
| extent:6 |
Fussnoten: | Gesehen am 05.03.2020 ; Elektronische Reproduktion der Druckausgabe |
Titel Quelle: | Enthalten in: Annals of oncology |
Ort Quelle: | Amsterdam [u.a. : Elsevier, 1990 |
Jahr Quelle: | 2018 |
Band/Heft Quelle: | 29(2018), 1, Seite 127-132 |
ISSN Quelle: | 1569-8041 |
Abstract: | Background - Perioperative chemotherapy is an established treatment of advanced gastric cancer patients. Treatment selection is based on clinical staging (cT). We aimed to establish and validate a prognostic score including clinical and molecular factors, to optimize treatment decisions for these patients. - Patients and methods - We analyzed 626 carcinomas of the stomach and of the gastro-esophageal junction from two academic centers including primarily resected and pre-/perioperatively treated patients. Patients were divided into a training (N = 269) and validation (N = 357) set. Expression of 11 target genes was measured by quantitative PCR in resected tumors. A risk score to predict overall survival (OS) was generated and validated. Intra-tumoral heterogeneity was assessed by analyzing 50 tumor areas from 10 patients. - Results - A risk score including the expression of CCL5, CTNNB1, EXOSC3 and LZTR1 and the clinical parameters cT, tumor localization and histopathologic type suggested two groups with a significant difference in OS [hazard ratio (HR) 0.30; 95% confidence interval (CI) 0.17-0.52]. The risk score was successfully validated in an independent cohort (HR 0.32; 95% CI 0.21-0.51; P < 0.001) as well as in subgroups of primarily resected (HR 0.30; 95% CI 0.17-0.54; P < 0.001) and pre-/perioperatively treated patients (HR 0.37; 95% CI 0.17-0.81; P = 0.009). A significant difference in OS of high- and low-risk patients was also found in primarily resected patients with intestinal (HR 0.45; 95% CI 0.23-0.90; P = 0.020) and nonintestinal-type carcinomas (HR 0.1; 95% CI 0.02-0.42; P < 0.001). Intra-tumor heterogeneity analysis indicated a classification reliability of 95% for a supposed analysis of three biopsies. - Conclusion - The identified risk score could substantially contribute to an improved management of gastric cancer patients in the context of perioperative chemotherapy. |
DOI: | doi:10.1093/annonc/mdx685 |
URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1093/annonc/mdx685 |
| Verlag: http://www.sciencedirect.com/science/article/pii/S0923753419350057 |
| DOI: https://doi.org/10.1093/annonc/mdx685 |
Datenträger: | Online-Ressource |
Sprache: | eng |
Sach-SW: | gastric carcinoma |
| gene expression |
| perioperative chemotherapy |
| prognosis |
| risk score |
K10plus-PPN: | 1691754986 |
Verknüpfungen: | → Zeitschrift |
¬A¬ novel pretherapeutic gene expression-based risk score for treatment guidance in gastric cancer / Bauer, Lukas [VerfasserIn]; 2018 (Online-Ressource)